SENETEK ANNOUNCES POSITIVE RESULTS FROM INITIAL PRECLINICAL TESTING OF ZEATIN AND OTHER NEW COMPOUNDS

Senetek has announced uniformly positive results from its initial multifaceted study of the effects of its patented adenine derivative, Zeatin, and two other new compounds representing new cytokinin classifications, AK801 and PRK124.

The study was conducted over a three-week period at the Department of Dermatology, University of California at Irvine using the hairless mouse model. This study model is designed to evaluate new compounds for safety and efficacy in the potential treatment of skin anti-aging and to investigate the mechanisms by which they affect the skin aging process.

The study evaluated three groups of mice that received daily applications of Zeatin, AK801 and PRK124, respectively, versus a placebo control group that received applications of only the topical vehicle and a therapeutic control group that received topical tretinoin 0.05 percent, tradename Renova, the only prescription drug approved for anti-aging in the U.S., according to the company.